Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)

NCT07719556 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma (MCL)

Interventions

DRUG: Orelabrutinib
DRUG: Obinutuzumab
DRUG: Venetoclax

Sponsor

The First Affiliated Hospital with Nanjing Medical University